Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
  • C08G65/32—Polymers modified by chemical after-treatment
  • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
  • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
  • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
  • C08G65/32—Polymers modified by chemical after-treatment
  • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
  • C08G65/325—Polymers modified by chemical after-treatment with inorganic compounds containing nitrogen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
  • C08G65/32—Polymers modified by chemical after-treatment
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
  • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
  • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
  • C08G65/32—Polymers modified by chemical after-treatment
  • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
  • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
  • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
  • C08L71/02—Polyalkylene oxides

Definitions

• the present invention relates to methods of preparing activated polymers such as polyalkylene oxides.
• the invention relates to methods of preparing linear polymers containing a terminal amine in high purity.
• the hydroxyl end-groups of the polymer must first be converted into reactive functional groups. This process is frequently referred to as “activation” and the product is called an “activated polyalkylene oxide.” Other polymers are similarly activated.
• Amine terminated polymers such as PEG-NH 2 are known. See Zalipsky et al. Eur. Polym. J. Vol.19 No.12., pp1177-1183. They can be used "as is” for direct conjugation to COOH groups found on some biologically active compounds. More often, PEG-NH 2 (or PEG-amine) is used as an intermediate which is further functionalized when other polymeric delivery systems are desired. For example, certain polymer-based drug delivery platform systems containing benzyl elimination systems, trimethyl lock systems, etc. can include PEG-NH 2 as a key intermediate in the process of synthesis. See Greenwald et al. J. Med. Chem. Vol. 42, No. 18, 3657-3667; Greenwald et al. J. Med. Chem. Vol. 47, No. 3, 726-734; Greenwald et al. J. Med. Chem. Vol. 43, No. 3, 475-487. The contents of each of the foregoing are hereby incorporated herein by reference.
• PEG-amines are also useful for conjugation (via reductive amination) with biologically active small molecules and polypeptides having available aldehyde groups. See also Nektar Advanced PEGylation catalog 2005-2006, page 24, the contents of which are incorporated herein by reference.
• PEG-amines could be prepared by preparing the PEG-halide, mesylate or tosylate from PEG-OH and thereafter performing a nucleophilic displacement reaction with aqueous ammonia (Hoffmann Reaction), sodium azide or potassium phthalimide (Gabriel Reagent).
• the reaction of the PEG-halide with the ammonia forms the PEG-amine directly.
• a major disadvantage is that a significant percentage of PEG-halide becomes hydrolyzed to form PEG-OH during the concentrated aqueous ammonia treatment. This is a particular concern when forming higher molecular weight PEG-amines.
• the higher molecular weight PEG the more PEG-OH is formed.
• PEG 5 ooo the amount is about 5% and with higher molecular weight PEG such as PEG 4 O 1 OOo the amount can be up to 20%. Consequently, the purity of the desired end product can decrease considerably.
• improved methods of preparing polymers having terminal amines include reacting a substantially non-antigenic polymer of the formula (I)
• R 1 is a reactive polymer terminal group such as a leaving group
• R 2 is a substantially non-antigenic polymer
• R 3 is a capping group or R 1 ; with a protected amine salt to form a polymer containing a terminal protected amine; and thereafter reacting the polymer containing the terminal protected amine resulting therefrom with an acid to remove the protecting group and form the polymer having a terminal amine.
• Examples of preferred reactive polymer terminal groups include leaving groups such as tosylate, mesylate, brosylate, tresylate, nosylate, Br, Cl, etc.
• the reaction of the polymer of Formula (I) with the protected amine salt is preferably carried out in a solvent such as dimethylformamide and the reactants are reacted under reactions conditions and for a time which are sufficient to substantially complete each of the reaction steps which ultimately causes formation of the terminal amine on the polymer.
• the polymer which is converted to the amine derivative is a PEG-tosylate and the tosylate group can be on at least one or more of the terminals of the PEG.
• the preferred protected amine salt is the potassium salt of methyl-tert-butyl imidodicarbonate (KNMeBoc) or the potassium salt of di-tert-butyl imidodicarbonate (KNB0C2).
• the purity of the polymer containing the terminal amine formed by process described herein is greater than about 95%, preferably greater than 98% and more preferably greater than 99%.
• the resulting terminal amine-containing polymers such as polyalkylene oxide derivatives thereof are prepared in high purity.
• product contaminants namely, the starting materials, such as mPEG-OH are not found in appreciable amounts, that is, they are found in amounts of less than about 5%, preferably less than about 2% and most preferably less than about 1%.
• the artisan can make end products which incorporate the PEG-amine more efficiently and at lower cost.
• the reaction to make the PEG-amine can be forced to completion and the excess small molecule reagents can be removed by recrystallization.
• the methods of the invention relate generally to the formation of polymers containing at least one terminal amine thereon.
• the polymers which can be modified using the processes described herein are substantially non-antigenic polymers.
• polyalkylene oxides are preferred and polyethylene glycols (PEG) are most preferred.
• PEG polyethylene glycols
• the process is sometimes described using PEG as the prototypical polymer. It should be understood, however, that the process is applicable to a wide variety of polymers which can be linear, substantially linear, branched, etc.
• one preferred aspect of the invention for preparing a polymer having a terminal amine includes: a) reacting a substantially non-antigenic polymer of the formula (I)
• Ri is a reactive polymer terminal group
• R 2 is a substantially non-antigenic polymer
• R 3 is a capping group or R 1 ; with a protected amine salt to form a polymer containing a terminal protected amine; and b) reacting the polymer containing the terminal protected amine resulting therefrom with an acid to remove the protecting group and form the polymer having a terminal amine.
• the term "reactive polymer terminal group" when used in context with Ri means a leaving group such as those known in the relevant art.
• suitable leaving groups includes tosylate, mesylate, brosylate, tresylate, nosylate, Br, Cl, etc.
• R 3 can be a capping group.
• capping groups shall be understood to mean a group which is found on the terminal of the polymer. In some aspects, it can be selected from any of CO 2 H, C 1 6 alkyls (CH 3 preferred), OH, etc. or other terminal groups as they are understood by those of ordinary skill.
• R 2 is also preferably a polymer that is water soluble at room temperature such as a polyalkylene oxide (PAO) and more preferably a polyethylene glycol such as mPEG or bis-activated PEG.
• PAO polyalkylene oxide
• a non-limiting list of such polymers therefore includes polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof, provided that the water solubility of the block copolymers is maintained.
• the polyethylene glycol (PEG) residue portion of R 2 can be selected from among: -CH 2 CH 2 - O-(CH 2 CH 2 O) X -CH 2 CH 2 - and
• x is the degree of polymerization, i.e. from about 10 to about 2,300
• R 3 is the same as R-i, and the resultant reactant is used in making bis-amine-terminated polymer compounds.
• Such bis-activated polymers can be of formula (Ia):
• the degree of polymerization for the polymer represents the number of repeating units in the polymer chain and is dependent on the molecular weight of the polymer.
• PAO's and PEG's can vary substantially in weight average molecular weight, preferably, R 2 has a weight average molecular weight of from about 200 to about 100,000
• the substantially non- antigenic polymer has a weight average molecular weight from about 2,000 to about 48,000 Daltons.
• R 2 can also be a "star-PEG” or multi-armed PEG's such as those described in Shearwater Corporation's 2001 catalog “Polyethylene Glycol and Derivatives for Biomedical Application", the disclosure of which is incorporated herein by reference.
• R 2 is part of a branched polymer corresponding to the polymers of the invention. Specifically, R 2 can be of the formula:
• n is an integer from about 10 to about 340, to preferably provide polymers having a total molecular weight of from about 12,000 to about 40,000; and at least 1 , but up to 3, of the terminal portion a of the residue is/are capped with a methyl or other lower alkyl and the remaining terminal group(s) is/are R 3 groups(s).
• n is an integer from about 10 to about 340, to preferably provide polymers having a total molecular weight of from about 12,000 to about 40,000; and at least 1 , but up to 3, of the terminal portion a of the residue is/are capped with a methyl or other lower alkyl and the remaining terminal group(s) is/are R 3 groups(s).
• Such compounds prior to terminal amination preferably include:
• R 7 is preferably methyl and all other variables are as preveiosly defined herein.
• One specific polymer capable of undergoing the amination process described herein is:
• R 7 is preferably methyl; z is an integer from 1 to about 120;
• L 1 and L 3 are independently selected bifunctional linking groups such s one of the following non-limiting compounds: -NH(CH 2 CH 2 O) y (CH 2 ) q NR9-,
• R 9-13 are independently selected from the same group as that which defines R 4 above, and preferably H or CH 3 ;
• R 6 is selected from the same group as that which defines R 4 , NO 2 ,
• R 2 is optionally selected from among one or more effectively non-antigenic materials such as dextran, polyvinyl alcohols, carbohydrate-based polymers, hydroxypropylmethacryl-amide (HPMA), polyalkylene oxides, and/or copolymers thereof.
• dextran polyvinyl alcohols
• carbohydrate-based polymers hydroxypropylmethacryl-amide (HPMA)
• HPMA hydroxypropylmethacryl-amide
• polyalkylene oxides and/or copolymers thereof.
• any of the water-soluble polymers described herein can be functionalized for attachment to the R 3 group(s), e.g. tosylate, mesylate, if required without undue experimentation prior to amination. Conversion or activation of the polymer (e.g. PEG) terminal OH into a tosylate, etc. has been reported in the art. See, for example US Patent No. 5,206344 and US Patent Application Pub. No. 2003/0149307, the contents of each of which are incorporated herein by reference.
• the formation of the polymer containing a terminal protected amine calls for reacting a substantially non-antigenic polymer of formula (I) containing one or more Ri groups e.g. reactive polymer terminal groups such as a tosylate, mesylate, brosylate, tresylate, nosylate, Br or Cl, with a protected amine salt.
• a substantially non-antigenic polymer of formula (I) containing one or more Ri groups e.g. reactive polymer terminal groups such as a tosylate, mesylate, brosylate, tresylate, nosylate, Br or Cl
• the reaction is carried out in a suitable solvent such as and without limitation dimethylformamide (DMF), tetrahydrofuran (THF), dimethylacetamide or similar reagents and mixtures thereof.
• the preferred solvent is dimethylformamide (DMF).
• Suitable solvents include those which are polar solvents such as methanol, ethanol, butanol, isopropanol, dioxane, etc. This step can be carried out at about room temperature although temperatures can range from about O 0 C to the reflux or boiling point of the solvent.
• polar solvents such as methanol, ethanol, butanol, isopropanol, dioxane, etc.
• This step can be carried out at about room temperature although temperatures can range from about O 0 C to the reflux or boiling point of the solvent.
• protected amine salts can be used in the processes of the invention. Generally, the protected amine salts can correspond to the formula:
• M is hydrogen or a metal chosen from lithium, sodium and potassium; Pi is included but not limited to the following list C(O)H, C(O)OMe 1 C(O)OBzI (Z), C(O)OtBu (Boc), C(O)OCH 2 CCI 3 (Troc), P(O)(OEt) 2 , CPh 3 (trityl); and R 4 is Pi or for example, C 1-6 alkyls, C 3-12 branched alkyls,
• a non-limiting list of some preferred suitable reagents includes without limitation, the potassium salt of di- tert-butyl imidodicarbonate (KNBoC 2 ), the lithium salt of di-tert-butyl imidodicarbonate (LiNBoC 2 ), the sodium salt of di-tert-butyl imidodicarbonate, etc.
• the protected amine salt is the potassium salt of di-tert-butyl imidodicarbonate (KNBoC 2 ).
• the protected amine salt can be selected from among potassium, sodium and lithium salts of NR 4 BoC, wherein R 4 is as shown above, for example,, C 1-6 alkyls, etc. and Boc is t- butylcarbonate.
• the preferred protected amine salt is the potassium salt of methyl-f-butyl imidodicarbonate (KNMeBoc).
• the protecting group e.g. Boc
• the protecting group is removed via hydrolyzing as mentioned above to for the desired PEG-amine derivatives in high purity.
• Non-Boc-protecting groups are removed using other art-recognized techniques.
• the high purity PEG-amine can then be used in any art-recognized way.
• it can be used for direct conjugation with CO 2 H groups or other suitable reactive groups found on biologically active targets of interest using techniques well known to those of ordinary skill.
• the PEG-amine can be used as a highly pure intermediate in more complex polymer linking systems such as the aforementioned benzyl- elimination (RNL) platforms or even as part of PEG-liposome systems.
• RNL systems can be made by reacting the PEG- amine with a suitable protected benzyl alcohol followed by deprotection and activation using techniques known to those of ordinary skill. See also the last example below.
• the polymer containing the terminal protected amine is formed, the polymer is deprotected, i.e. the protecting group is removed, in order to form the desired amine-terminated polymer.
• the deprotecting can be accomplished using an acid such as and without limitation, HCI solution in Et 2 O (ether) or dioxane, acetic acid, dichloroacetic acid, formic acid, and trifluoroacetic acid in dichloromethane (or dichloroethane) (from 15% to 35%), or other solvent compatible to dissolve the acid and allow deprotection under organic environment. In many aspects of the invention, 20% trifluoroacetic acid in dichloromethane is preferred.
• the methods of the present invention are preferably carried out using at least about an equimolar amount of the reactants. More preferably, the protected amine salt is present in a molar excess with respect to the compound of formula (I). Preferably, the protected amine salt is present in at least about a 3-5 fold molar excess to the mPEG is about 5 to about 1. When delta-PEG (bis-PEG or activated on each terminal) is used, the molar excess is about twice as high, e.g. about a 6-10 fold molar excess. Similar ratios are used per amine group to be added if branched polymers are used.
• a polyalkylene oxide (PAO) such as uncapped PEG-OH (di-PEG OH) or mPEG is converted into a compound of formula (Na) or (lib):
• a polyalkylene oxide (PAO) such as uncapped PEG-OH (di-PEG OH) or mPEG is converted into a compound of formula (Na) or (lib):
• R 2 is a PAO such as PEG or mPEG;
• X is O, S, or NHR 8 , wherein Re is, hydrogen, Ci -6 alkyls, C 3- I 2 branched alkyls, C 3-8 cycloalkyls, Ci -6 substituted alkyls, C 3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, Ci -6 heteroalkyls, substituted Ci -6 heteroalkyls, Ci -6 alkoxy, phenoxy and Ci -6 heteroalkoxy, etc; and
• R 7 is for example a methyl, halogen, nitro, fluoromethyl, difluoromethyl, trifluromethyl, substituted carboxyl, and a multi-halogen substituted benzenesulfonyl. CH 3 is preferred.
• the protecting group e.g. Boc
• the protecting group is removed via hydrolyzing as mentioned above to for the desired PEG-amine derivatives in high purity.
• the high purity PEG-amine can then be used in any art-recognized way.
• it can be used
• PEG-OTs PEG-tosylate
• the corresponding 20KDa ⁇ PEG-amine is made from 20KDa ⁇ PEG-OTs prepared in the same way above except that PEG 20KDa is used in place of PEG 40KDa.
• Compound 6 is made under the same conditions of 2 in Example 1. The structure of 6 is confirmed by NMR.
• Compound 7 is made under the same conditions of 3 in Example 1. The structure of 7 is confirmed by NMR.
• Compound 8 is made under the same conditions of 4 in Example 1. The structure of 8 is confirmed by NMR.
• PEG-OTs PEG-tosylate
• the 30KDa mPEG-NH 2 of Example 4 is converted into the activated PEG linker according to the following reaction scheme.
• the final product can be used for conjugation to any number of biologically active polypeptides, enzymes, proteins, small molecules, etc. having an available amine or hydroxyl thereon for conjugation.
• the procedures for such conjugation reactions have been described, for example, in commonly-assigned U.S. Patent No. 6,180,095, the contents of which are incorporated herein by reference, or the aforementioned Greenwald et al. J. Med. Chem. Vol. 42, No. 18, 3657-3667.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Polymers & Plastics (AREA)
• General Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Inorganic Chemistry (AREA)
• Polyethers (AREA)
• Medicinal Preparation (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=37902700

Family Applications (1)

Country Status (10)

Families Citing this family (13)

Family Cites Families (11)

• 2005
  • 2005-10-04 US US11/242,656 patent/US7601798B2/en not_active Expired - Fee Related
• 2006
  • 2006-09-29 KR KR1020087010397A patent/KR20080056267A/ko not_active Withdrawn
  • 2006-09-29 US US11/537,172 patent/US7569657B2/en not_active Expired - Fee Related
  • 2006-09-29 AU AU2006302585A patent/AU2006302585A1/en not_active Abandoned
  • 2006-09-29 WO PCT/US2006/038562 patent/WO2007044319A2/en not_active Ceased
  • 2006-09-29 CN CNA2006800455829A patent/CN101321516A/zh active Pending
  • 2006-09-29 CA CA002623542A patent/CA2623542A1/en not_active Abandoned
  • 2006-09-29 EP EP06816091A patent/EP1931313A4/en not_active Withdrawn
  • 2006-09-29 JP JP2008534615A patent/JP2009510253A/ja active Pending
  • 2006-10-02 TW TW095136519A patent/TW200718730A/zh unknown
• 2008
  • 2008-03-25 IL IL190415A patent/IL190415A0/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events